GlassScriptPhysician profile
Anita Jasani
NPI 1912012519
$17,892.37
in general payments reported to CMS, 2019-2025
44 companies · $3,547 in 2025
The $3,547 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,691 · 2020: $1,693 · 2021: $2,113 · 2022: $2,351 · 2023: $3,324 · 2024: $3,173 · 2025: $3,547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,043.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,040.28 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $2,110.67 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,792.53 | 2019-2025 | |
| Amgen INC. | $1,265.37 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $1,215.24 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $992.33 | 2022-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $984.92 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $826.94 | 2019-2025 | Jardiance |
| Pfizer INC. | $792.35 | 2019-2025 | |
| Lilly USA, LLC | $615.44 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Corcept Therapeutics | $580.30 | 2021-2025 | Korlym |
| Merck Sharp & Dohme LLC | $545.76 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amarin Pharma, INC. | $435.89 | 2019-2022 | |
| Daiichi Sankyo INC. | $315.01 | 2019-2023 | Injectafer |
| Abbott Laboratories | $211.55 | 2022-2025 | Freestyle Libre 3 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $190.85 | 2021-2023 | Aplenzin, Wellbutrin |
| Sanofi-Aventis U.S. LLC | $183.02 | 2019-2021 | |
| Exact Sciences Corporation | $176.24 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $147.39 | 2024-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $135.76 | 2024-2025 | Veozah |
| Madrigal Pharmaceuticals | $135.00 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Ambu INC. | $117.88 | 2023 | |
| Currax Pharmaceuticals LLC | $100.52 | 2022-2025 | Contrave |
| Genentech USA, INC. | $98.27 | 2019-2020 | |
| Dynavax Technologies Corporation | $93.97 | 2023-2025 | Heplisav-B |
| Mylan Specialty L.P. | $82.19 | 2020 | |
| Esperion Therapeutics, INC. | $72.97 | 2021-2025 | Nexletol |
| Cequr Corporation | $67.13 | 2024 | Cequr Simplicity |
| Sanofi Pasteur INC. | $57.29 | 2019-2022 | |
| Insightec,INC | $46.87 | 2025 | Exablate |
| Seqirus USA INC | $45.07 | 2022-2025 | Fluad Quadrivalent, Flucelvax, Fluad |
| Novartis Pharmaceuticals Corporation | $44.84 | 2024-2025 | |
| Althera Pharmaceuticals LLC | $40.26 | 2021 | |
| Xeris Pharmaceuticals, INC. | $35.58 | 2025 | Recorlev |
| Teva Pharmaceuticals USA, INC. | $29.79 | 2019-2024 | Austedo Xr |
| Topcon Healthcare Solutions, INC. | $29.48 | 2020 | |
| Abiomed | $19.59 | 2025 | |
| Phadia US INC. | $18.35 | 2025 | Immunocap |
| Renalytix Ai, INC. | $18.26 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Eisai INC. | $14.25 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.19 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.06 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $13.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anita Jasani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.